OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
Key Highlights
- ➤OKYO enrolls first patients in Phase 3 NEPTUNE trial of urcosimod
- ➤NEPTUNE evaluates urcosimod across clinical sites in the United States and Europe
- ➤Patients receive four daily drops for 12 weeks in NEPTUNE
- ➤Primary endpoint measures change in ocular pain using VAS score
Expert Statements
Melissa Toyos, MD
“Neuropathic corneal pain is one of the most debilitating conditions I see in my practice, and right now we have no FDA approved therapy to offer these patients, many of whom have tried everything and are still suffering”
Melissa Toyos, MD
“I believe this trial represents an important step toward determining whether this investigational therapy can address the significant unmet need faced by patients with neuropathic corneal pain.”
Flavio Mantelli, Chief Medical Officer of OKYO Pharma
“The activation of the first site and initiation of OKYO’s NEPTUNE trial represent an important milestone for building the clinical evidence necessary to support the potential first disease modifying treatment for neuropathic corneal pain (NCP)”
Flavio Mantelli, Chief Medical Officer of OKYO Pharma
“We are honored to have Dr. Toyos enroll the first patients in the study while activation of other sites expands across leading U.S. medical centers.”
* NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain * First patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).
"Neuropathic corneal pain is one of the most debilitating conditions I see in my practice, and right now we have no FDA approved therapy to offer these patients, many of whom have tried everything and are still suffering,” said Melissa Toyos, MD. “I believe this trial represents an important step toward determining whether this investigational therapy can address the significant unmet need faced by patients with neuropathic corneal pain.”
Get started
Create a free account to read the full story.